Active Removal of IntraCerebral Hematoma Via Active Irrigation
Status unknown · Not applicable · NCT05118997
Conditions: Cerebral Hemorrhage, Intraventricular Hemorrhage
At a glance
- Research payments reported, 2025
- $149,616
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 60
About the trial
- Sponsor
- IRRAS (with University of Helsinki, Northwestern University, West Virginia University, Klinikum Bergmannstrost, Stony Brook University Hospital, Icahn School of Medicine at Mount Sinai, Buffalo General Medical Center)
- Tested
- IRRAflow (device), EVD (device)
- Dates
- Started 2021-10-25; completion 2025-09
- Results posted
- Not yet
Study evaluating if active irrigation by IRRAflow® with infusion of tPA will reduce the time needed for clearance of intracerebral and intraventricular hemorrhage compared with passive drainage.
From ClinicalTrials.gov, last updated 2024-08-01. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Irras USA, Inc. reported $149,616 in research payments for this study in 2025 (10 payments).
Products named: Irraflow
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Christopher P. Kellner, M.D. Neurosurgery · New York, NY
- Adnan H. Siddiqui, MD, PHD Neurosurgery · Williamsville, NY
- Nicholas J. Brandmeir, MD Neurosurgery · Hershey, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Mount Sinai Hospital, NY $88,550
- University of Buffalo $57,065
- Wvu Office of Research Corporation $4,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.